LIDDS AB (publ) (LIDDS.ST)
SEK 0.11
(-3.65%)
SEK 0.11
(-3.65%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 17.65 Million SEK | -31.89% |
| 2022 | 25.92 Million SEK | -53.36% |
| 2021 | 55.57 Million SEK | 2.53% |
| 2020 | 54.2 Million SEK | -65.71% |
| 2019 | 158.09 Million SEK | -3.24% |
| 2018 | 163.37 Million SEK | 24.9% |
| 2017 | 130.81 Million SEK | 8.1% |
| 2016 | 121.01 Million SEK | 18.24% |
| 2015 | 102.34 Million SEK | 3.7% |
| 2014 | 98.69 Million SEK | 28.53% |
| 2013 | 76.78 Million SEK | 6.41% |
| 2012 | 72.16 Million SEK | -2.55% |
| 2011 | 74.05 Million SEK | 22.07% |
| 2010 | 60.66 Million SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 10.52 Million SEK | -22.95% |
| 2024 Q1 | 13.66 Million SEK | -22.6% |
| 2023 Q2 | 42.21 Million SEK | -16.32% |
| 2023 Q3 | 36.41 Million SEK | -13.73% |
| 2023 Q4 | 17.65 Million SEK | -51.52% |
| 2023 FY | 17.65 Million SEK | -31.89% |
| 2023 Q1 | 50.44 Million SEK | 94.61% |
| 2022 Q1 | 48.02 Million SEK | -13.59% |
| 2022 Q4 | 25.92 Million SEK | -28.24% |
| 2022 FY | 25.92 Million SEK | -53.36% |
| 2022 Q2 | 40.91 Million SEK | -14.81% |
| 2022 Q3 | 36.12 Million SEK | -11.71% |
| 2021 Q3 | 63.86 Million SEK | -12.8% |
| 2021 Q2 | 73.23 Million SEK | 73.12% |
| 2021 FY | 55.57 Million SEK | 2.53% |
| 2021 Q1 | 42.3 Million SEK | -21.96% |
| 2021 Q4 | 55.57 Million SEK | -12.97% |
| 2020 FY | 54.2 Million SEK | -65.71% |
| 2020 Q1 | 23.75 Million SEK | -84.97% |
| 2020 Q2 | 38.82 Million SEK | 63.4% |
| 2020 Q3 | 63.56 Million SEK | 63.73% |
| 2020 Q4 | 54.2 Million SEK | -14.72% |
| 2019 Q2 | 166.35 Million SEK | 3.13% |
| 2019 Q3 | 165.64 Million SEK | -0.42% |
| 2019 Q1 | 161.3 Million SEK | -1.27% |
| 2019 Q4 | 158.09 Million SEK | -4.56% |
| 2019 FY | 158.09 Million SEK | -3.24% |
| 2018 Q1 | 142.31 Million SEK | 8.8% |
| 2018 FY | 163.37 Million SEK | 24.9% |
| 2018 Q4 | 163.37 Million SEK | -3.56% |
| 2018 Q3 | 169.41 Million SEK | 4.17% |
| 2018 Q2 | 162.62 Million SEK | 14.27% |
| 2017 Q1 | 114.01 Million SEK | -5.78% |
| 2017 Q2 | 117.98 Million SEK | 3.48% |
| 2017 Q4 | 130.81 Million SEK | -0.21% |
| 2017 Q3 | 131.08 Million SEK | 11.11% |
| 2017 FY | 130.81 Million SEK | 8.1% |
| 2016 Q3 | 117.33 Million SEK | 19.69% |
| 2016 Q2 | 98.02 Million SEK | -2.23% |
| 2016 Q1 | 100.26 Million SEK | -2.03% |
| 2016 FY | 121.01 Million SEK | 18.24% |
| 2016 Q4 | 121.01 Million SEK | 3.13% |
| 2015 Q2 | 92.97 Million SEK | -3.12% |
| 2015 Q4 | 102.34 Million SEK | 11.61% |
| 2015 FY | 102.34 Million SEK | 3.7% |
| 2015 Q1 | 95.96 Million SEK | -2.76% |
| 2015 Q3 | 91.7 Million SEK | -1.37% |
| 2014 Q1 | 75.87 Million SEK | -1.18% |
| 2014 Q2 | 111.38 Million SEK | 46.79% |
| 2014 Q3 | 101.17 Million SEK | -9.17% |
| 2014 Q4 | 98.69 Million SEK | -2.45% |
| 2014 FY | 98.69 Million SEK | 28.53% |
| 2013 Q1 | - SEK | 0.0% |
| 2013 Q4 | 76.78 Million SEK | 0.0% |
| 2013 FY | 76.78 Million SEK | 6.41% |
| 2012 FY | 72.16 Million SEK | -2.55% |
| 2011 FY | 74.05 Million SEK | 22.07% |
| 2010 FY | 60.66 Million SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 118.45 Million SEK | 85.095% |
| Ziccum AB (publ) | 14.97 Million SEK | -17.92% |
| Modus Therapeutics Holding AB (publ) | 20.04 Million SEK | 11.906% |
| BioArctic AB (publ) | 1.18 Billion SEK | 98.511% |
| Sprint Bioscience AB (publ) | 62.37 Million SEK | 71.696% |
| Mendus AB (publ) | 755.95 Million SEK | 97.665% |
| Genovis AB (publ.) | 288.85 Million SEK | 93.888% |
| Intervacc AB (publ) | 259.61 Million SEK | 93.199% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 41.95 Million SEK | 57.923% |
| Active Biotech AB (publ) | 44 Million SEK | 59.875% |
| Magle Chemoswed Holding AB (publ) | 278.74 Million SEK | 93.666% |
| Bio-Works Technologies AB (publ) | 62.15 Million SEK | 71.594% |
| Aptahem AB (publ) | 63.02 Million SEK | 71.987% |
| Vicore Pharma Holding AB (publ) | 496.24 Million SEK | 96.442% |
| Kancera AB (publ) | 65.64 Million SEK | 73.105% |
| Infant Bacterial Therapeutics AB (publ) | 351.33 Million SEK | 94.975% |
| Fluicell AB (publ) | 9.34 Million SEK | -89.026% |
| Saniona AB (publ) | 64.14 Million SEK | 72.476% |
| Lipigon Pharmaceuticals AB (publ) | 33.6 Million SEK | 47.458% |
| Biovica International AB (publ) | 131.4 Million SEK | 86.565% |
| Spago Nanomedical AB (publ) | 52.98 Million SEK | 66.679% |
| AcouSort AB (publ) | 34.51 Million SEK | 48.845% |
| Xintela AB (publ) | 18.39 Million SEK | 4.023% |
| Abliva AB (publ) | 87.49 Million SEK | 79.823% |
| Egetis Therapeutics AB (publ) | 760.2 Million SEK | 97.678% |
| Karolinska Development AB (publ) | 1.25 Billion SEK | 98.597% |
| OncoZenge AB (publ) | 20.34 Million SEK | 13.201% |
| Amniotics AB (publ) | 26.08 Million SEK | 32.32% |
| 2cureX AB (publ) | 16.62 Million SEK | -6.195% |
| CombiGene AB (publ) | 120.61 Million SEK | 85.362% |
| Asarina Pharma AB (publ) | 6.07 Million SEK | -190.522% |
| Calliditas Therapeutics AB (publ) | 1.9 Billion SEK | 99.071% |
| Camurus AB (publ) | 1.9 Billion SEK | 99.075% |
| Corline Biomedical AB | 100.1 Million SEK | 82.364% |
| IRLAB Therapeutics AB (publ) | 177.12 Million SEK | 90.032% |
| Isofol Medical AB (publ) | 140.59 Million SEK | 87.443% |
| I-Tech AB | 152.44 Million SEK | 88.419% |
| Hansa Biopharma AB (publ) | 1.01 Billion SEK | 98.266% |
| Cyxone AB (publ) | 43.65 Million SEK | 59.558% |
| ExpreS2ion Biotech Holding AB (publ) | 78.69 Million SEK | 77.564% |
| Biosergen AB | 7.2 Million SEK | -145.174% |
| Cantargia AB (publ) | 223.71 Million SEK | 92.108% |
| NextCell Pharma AB | 81.28 Million SEK | 78.281% |
| Xspray Pharma AB (publ) | 765.26 Million SEK | 97.693% |
| Elicera Therapeutics AB (publ) | 30.17 Million SEK | 41.487% |
| Nanologica AB (publ) | 77.42 Million SEK | 77.198% |
| SynAct Pharma AB | 228.01 Million SEK | 92.257% |
| Annexin Pharmaceuticals AB (publ) | 26.76 Million SEK | 34.032% |
| Stayble Therapeutics AB (publ) | 21.7 Million SEK | 18.651% |
| Lipum AB (publ) | 12.11 Million SEK | -45.789% |
| BioInvent International AB (publ) | 1.4 Billion SEK | 98.739% |
| Alzinova AB (publ) | 123.18 Million SEK | 85.668% |
| Oncopeptides AB (publ) | 238.37 Million SEK | 92.594% |
| Pila Pharma AB (publ) | 8.45 Million SEK | -108.811% |
| Guard Therapeutics International AB (publ) | 85.22 Million SEK | 79.285% |
| Scandinavian ChemoTech AB (publ) | 14.86 Million SEK | -18.737% |
| Simris Alg AB (publ) | 174.55 Million SEK | 89.886% |
| Diamyd Medical AB (publ) | 217.03 Million SEK | 91.865% |
| Xbrane Biopharma AB (publ) | 653.5 Million SEK | 97.298% |
| Ascelia Pharma AB (publ) | 87.07 Million SEK | 79.724% |
| Diagonal Bio AB (publ) | 28.5 Million SEK | 38.07% |